Merck & Co Financial Statements (MRK)
|
|
|
|
Report date
|
|
|
31.12.2023 |
26.02.2024 |
11.04.2024 |
25.02.2025 |
24.02.2026 |
|
04.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
59 871 |
60 115 |
60 115 |
64 168 |
64 926 |
|
65 593 |
|
Operating Income, bln rub |
|
|
2 982 |
2 954 |
2 954 |
20 221 |
23 486 |
|
18 098 |
|
EBITDA, bln rub |
? |
|
6 854 |
6 907 |
6 907 |
25 706 |
29 324 |
|
22 692 |
|
Net profit, bln rub |
? |
|
365.0 |
365.0 |
365.0 |
17 117 |
18 254 |
|
8 935 |
|
|
OCF, bln rub |
? |
|
13 006 |
13 006 |
13 006 |
21 468 |
16 472 |
|
17 890 |
|
CAPEX, bln rub |
? |
|
3 863 |
3 863 |
3 863 |
3 372 |
4 112 |
|
3 775 |
|
FCF, bln rub |
? |
|
9 143 |
9 143 |
9 143 |
18 096 |
12 360 |
|
14 115 |
|
Dividend payout, bln rub
|
|
|
7 445 |
7 445 |
7 445 |
7 840 |
8 176 |
|
8 231 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
2 040% |
2 040% |
2 040% |
45.8% |
44.8% |
|
92.1% |
|
|
OPEX, bln rub |
|
|
40 912 |
41 035 |
43 989 |
28 754 |
23 245 |
|
31 693 |
|
Cost of production, bln rub |
|
|
15 977 |
16 126 |
16 126 |
15 193 |
18 195 |
|
15 802 |
|
R&D, bln rub |
|
|
30 530 |
30 531 |
30 531 |
17 938 |
12 514 |
|
22 149 |
|
Interest expenses, bln rub |
|
|
1 146 |
1 146 |
1 146 |
1 271 |
1 357 |
|
1 043 |
|
|
Assets, bln rub |
|
|
106 675 |
106 675 |
106 675 |
117 106 |
136 866 |
|
128 685 |
|
Net Assets, bln rub |
? |
|
37 581 |
37 581 |
37 581 |
46 313 |
52 606 |
|
45 878 |
|
Debt, bln rub |
|
|
36 268 |
36 268 |
36 268 |
38 270 |
50 534 |
|
49 117 |
|
Cash, bln rub |
|
|
7 161 |
7 093 |
7 093 |
13 689 |
14 565 |
|
5 702 |
|
Net debt, bln rub |
|
|
29 107 |
29 175 |
29 175 |
24 581 |
35 969 |
|
43 415 |
|
|
Ordinary share price, rub |
|
|
109.0 |
109.0 |
109.0 |
99.5 |
105.3 |
|
111.4 |
|
Number of ordinary shares, mln |
|
|
2 537 |
2 607 |
2 607 |
2 532 |
2 502 |
|
2 472 |
|
|
Market cap, bln rub |
|
|
276 584 |
284 231 |
284 231 |
251 883 |
263 361 |
|
275 382 |
|
EV, bln rub |
? |
|
305 691 |
313 406 |
313 406 |
276 464 |
299 330 |
|
318 797 |
|
Book value, bln rub |
|
|
-1 627 |
-1 627 |
-1 627 |
8 275 |
4 346 |
|
-1 448 |
|
|
EPS, rub |
? |
|
0.14 |
0.14 |
0.14 |
6.76 |
7.30 |
|
3.61 |
|
FCF/share, rub |
|
|
3.60 |
3.51 |
3.51 |
7.15 |
4.94 |
|
5.71 |
|
BV/share, rub |
|
|
-0.64 |
-0.62 |
-0.62 |
3.27 |
1.74 |
|
-0.59 |
|
|
EBITDA margin, % |
? |
|
11.4% |
11.5% |
11.5% |
40.1% |
45.2% |
|
34.6% |
|
Net margin, % |
? |
|
0.61% |
0.61% |
0.61% |
26.7% |
28.1% |
|
13.6% |
|
FCF yield, % |
? |
|
3.31% |
3.22% |
3.22% |
7.18% |
4.69% |
|
5.13% |
|
ROE, % |
? |
|
0.97% |
0.97% |
0.97% |
37.0% |
34.7% |
|
19.5% |
|
ROA, % |
? |
|
0.34% |
0.34% |
0.34% |
14.6% |
13.3% |
|
6.94% |
|
|
P/E |
? |
|
757.8 |
778.7 |
778.7 |
14.7 |
14.4 |
|
30.8 |
|
P/FCF |
|
|
30.3 |
31.1 |
31.1 |
13.9 |
21.3 |
|
19.5 |
|
P/S |
? |
|
4.62 |
4.73 |
4.73 |
3.93 |
4.06 |
|
4.20 |
|
P/BV |
? |
|
-170.0 |
-174.7 |
-174.7 |
30.4 |
60.6 |
|
-190.2 |
|
EV/EBITDA |
? |
|
44.6 |
45.4 |
45.4 |
10.8 |
10.2 |
|
14.0 |
|
Debt/EBITDA |
|
|
4.25 |
4.22 |
4.22 |
0.96 |
1.23 |
|
1.91 |
|
|
R&D/CAPEX, % |
|
|
790.3% |
790.3% |
790.3% |
532.0% |
304.3% |
|
586.7% |
|
|
CAPEX/Revenue, % |
|
|
6.45% |
6.43% |
6.43% |
5.25% |
6.33% |
|
5.76% |
|
| Merck & Co shareholders |
